Related Experiment Video
Updated: Jul 29, 2025
07:34
Use of Animal Model of Sepsis to Evaluate Novel Herbal Therapies
Published on: April 11, 2012
19.5K
Protective Effect of a Novel RIPK1 Inhibitor, Compound 4-155, in Systemic Inflammatory Response Syndrome and Sepsis
Zhong-Yi Ling1,2, Quan-Zhen Lv2, Jiao Li2
1School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou, China.
Inflammation
|May 25, 2023
Summary
A novel compound, 4-155, selectively targets RIPK1 to inhibit necroptosis and reduce inflammation. This compound shows significant potential for treating systemic inflammatory response syndrome (SIRS) and sepsis.
Area of Science:
- Biochemistry
- Pharmacology
- Immunology
Background:
- Excessive inflammation drives tissue damage in SIRS and sepsis.
- Targeting RIPK1 is a promising anti-inflammatory strategy.
Purpose of the Study:
- Identify novel RIPK1 inhibitors for treating SIRS and sepsis.
- Evaluate the efficacy and mechanism of a new compound, 4-155.
Main Methods:
- Selective RIPK1 targeting compound 4-155 identified.
- In vitro assays: necroptosis inhibition, RIPK1 binding confirmation (DARTS, IP, kinase assay, immunofluorescence).
- In vivo studies: TNF-induced SIRS and sepsis models in mice, cytokine level analysis.
Main Results:
- Compound 4-155 potently inhibits necroptosis by blocking RIPK1 phosphorylation.
- 4-155 demonstrates superior efficacy to Nec-1s in vivo, increasing SIRS mouse survival to 90% at 6 mg/kg.
- Reduced pro-inflammatory cytokines (TNF-α, IL-6) and protected liver/kidney in vivo.
Conclusions:
- Compound 4-155 is a potent RIPK1 inhibitor with significant anti-inflammatory effects.
- 4-155 offers a promising therapeutic lead for SIRS and sepsis treatment.
- Selective RIPK1 inhibition by 4-155 provides a novel approach to managing excessive inflammation.
